Virica is the first company to develop and commercialize Viral Sensitizers (VSEs) to solve the key challenges of manufacturing and efficacy facing viral medicines. VSEs are small molecules that reduce the anti-viral responses of cells, thereby improving product yields and therapeutic efficacy for gene therapies, vaccines and oncolytic viruses. Virica's business model includes developing and supplying VSEs as manufacturing reagents to clients and deploying VSEs to build better therapies. Virica’s dual pipeline of manufacturing and therapeutic products offers a balanced risk portfolio. The manufacturing business will generate significant short term revenues through product sales and services, while longer term revenues will be generated through development and out-licensing of an internal therapeutics pipeline and co-developed products. Virica’s leadership team is experienced in building and operating hyper-growth companies. Virica is raising a Series A round totalling US$5 million in order to build on the traction built by the company and allow it to reach its full potential.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2018
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
VSE molecules for manufacturing and therapeutics
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
